MK-3475-091 KEYNOTE-091 PEARLS
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS) - KEYNOTE-091
Detalhes
Destaques